Data gathered: December 26
AI Stock Analysis - Atricure (ATRC)
Analysis generated November 22, 2024. Powered by Chat GPT.
AtriCure is a leading medical device company specializing in treatments for atrial fibrillation and related conditions. The company focuses on developing innovative products and technologies for the treatment of cardiac arrhythmias and surgical ablation. Their portfolio includes proprietary devices and systems designed for both minimally invasive and open surgical procedures, positioning AtriCure as a prominent player in its field.
Stock Alerts - Atricure (ATRC)
 |
Atricure | December 17 Employee Rating is up by 2.2% over the last month. |
|
Atricure | December 5 Price is down by -5.1% in the last 24h. |
|
Atricure | November 26 Business Outlook among employees is up by 3.4% over the last month. |
|
Atricure | November 12 Employee Rating is up by 2.2% over the last month. |
Alternative Data for Atricure
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 56 | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Employee Rating | 94 | Sign up | Sign up | Sign up |
| Google Trends | 21 | Sign up | Sign up | Sign up |
| Patents | 150 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 30 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,276 | Sign up | Sign up | Sign up |
| Instagram Followers | 763 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 384 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,589 | Sign up | Sign up | Sign up |
| Twitter Mentions | 7 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,100 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 93 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,250 | Sign up | Sign up | Sign up |
About Atricure
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally.
| Price | $30.49 |
| Target Price | Sign up |
| Volume | 37,040 |
| Market Cap | $1.49B |
| Year Range | $19.86 - $38.2 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Medical & Dental Instruments |
In the news
 |
AtriCure, Inc. (NASDAQ:ATRC) Shares Bought by Geode Capital Management LLCDecember 26 - ETF Daily News |
|
Barclays PLC Decreases Stake in AtriCure, Inc. (NASDAQ:ATRC)December 23 - ETF Daily News |
 |
JPMorgan Chase & Co. Reaffirms “Overweight” Rating for AtriCure (NASDAQ:ATRC)December 20 - ETF Daily News |
 |
Comparing AtriCure (NASDAQ:ATRC) & Aethlon Medical (NASDAQ:AEMD)December 15 - ETF Daily News |
|
BNP Paribas Financial Markets Sells 79,020 Shares of AtriCure, Inc. (NASDAQ:ATRC)December 15 - ETF Daily News |
|
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of “Buy” from AnalystsDecember 14 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 116M | 29M | 87M | -7.9M | -5.3M | -0.170 |
| Q2 '24 | 116M | 29M | 87M | -8M | -7M | -0.170 |
| Q1 '24 | 109M | 28M | 81M | -13M | -9.3M | -0.280 |
| Q4 '23 | 107M | 27M | 80M | -9.8M | -5.7M | -0.210 |
| Q3 '23 | 98M | 24M | 74M | -9.1M | -5.3M | -0.200 |
Insider Transactions View All
| Yuen Maggie filed to sell 8,970 shares at $24.1. August 19 '24 |
| Privitera Salvatore filed to buy 103,290 shares at $22.3. May 31 '24 |
| Noznesky Justin J filed to sell 71,284 shares at $24.1. May 3 '24 |
| Noznesky Justin J filed to sell 72,784 shares at $30.4. April 3 '24 |
| Dahlquist Karl S. filed to sell 50,954 shares at $32.2. March 20 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Josh Gottheimer |
Aug 15, 24 | Buy | $1K - $15K |
| Josh Gottheimer |
Jul 9, 24 | Sell | $1K - $15K |
Read more about Atricure (ATRC) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Atricure?
The Market Cap of Atricure is $1.49B.
What is the current stock price of Atricure?
Currently, the price of one share of Atricure stock is $30.49.
How can I analyze the ATRC stock price chart for investment decisions?
The ATRC stock price chart above provides a comprehensive visual representation of Atricure's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Atricure shares. Our platform offers an up-to-date ATRC stock price chart, along with technical data analysis and alternative data insights.
Does ATRC offer dividends to its shareholders?
As of our latest update, Atricure (ATRC) does not offer dividends to its shareholders. Investors interested in Atricure should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Atricure?
Some of the similar stocks of Atricure are Align Technology, Dentsply, LeMaitre Vascular, iRhythm Technologies, and NovoCure.
.